Related Experiment Video
Updated: Jun 20, 2026

Generating Genetically Modified Plasmodium berghei Sporozoites
Published on: May 5, 2023
The development of the RTS,S malaria vaccine candidate: challenges and lessons
1Infectious Diseases Development, Global Health Division, Bill & Melinda Gates Foundation, PO Box 23350, Seattle, WA, USA. rip.ballou@gatesfoundation.org
Insights
The RTS,S malaria vaccine candidate aims to protect young children in Africa from Plasmodium falciparum. Ongoing trials and Phase II data suggest it could significantly reduce malaria burden when integrated into immunization programs.
Area of Science:
- Vaccinology
- Infectious Disease Control
- Pediatric Health
Background:
- Malaria remains a significant threat to infants and young children in sub-Saharan Africa.
- Plasmodium falciparum is a primary cause of severe malaria in endemic regions.
- Developing a safe and effective malaria vaccine for widespread use presents unique challenges.
Observation:
- The RTS,S vaccine candidate is the most advanced globally for malaria prevention.
- A pivotal Phase III efficacy trial of RTS,S is currently underway in Africa.
- Phase II program data show encouraging results for vaccine efficacy and safety.
Findings:
- The RTS,S vaccine is designed for administration through the Expanded Program for Immunization (EPI).
- The vaccine aims to reduce the risk of clinical malaria disease in early life.
- Potential for reducing severe malaria and associated co-morbidities is being investigated.
Implications:
- RTS,S could become a crucial new tool in combating malaria in sub-Saharan Africa.
- Successful vaccine deployment may significantly decrease the burden of childhood malaria.
- The development highlights the complexity of novel vaccine technologies and the importance of global health partnerships.
Abstract:
RTS,S is the world's most advanced malaria vaccine candidate and is intended to protect infants and young children living in malaria endemic areas of sub-Saharan Africa against clinical disease caused by Plasmodium falciparum. Recently, a pivotal Phase III efficacy trial of RTS,S began in Africa. The goal of the programme has been to develop a vaccine that will be safe and effective when administered via the Expanded Program for Immunization (EPI) and significantly reduce the risk of clinically important malaria disease during the first years of life. If a similar reduction in the risk of severe malaria and other important co-morbidities associated with malaria infection can be achieved, then the vaccine could become a major new tool for reducing the burden of malaria in sub-Saharan Africa. Encouraging data from the ongoing phase II programme suggest that these goals may indeed be achievable. This review discusses some of the unique challenges that were faced during the development of this vaccine, highlights the complexity of developing new vaccine technologies and illustrates the power of partnerships in the ongoing fight against this killer disease.
More Related Videos
08:46Myeloid Cell Isolation from Mouse Skin and Draining Lymph Node Following Intradermal Immunization with Live Attenuated Plasmodium Sporozoites
Published on: May 18, 2016
09:13Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy
Published on: November 1, 2011
Related Concept Videos
Malaria
Respiratory Syncytial Virus Disease
Symbiosis
Microorganisms in Medicine and Therapeutics